Has Alan Cohen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,469,302 in general payments to Alan Cohen, MD across 1,755 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alan Cohen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alan Cohen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alan Cohen, MD

Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1245203371

Payments from drug & device makers

$1,469,302in general payments, 2019–2025

Across 1,755 payments — averaging $837.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$567K
Amgen$238K
Novo Nordisk$199K
Sanofi-aventis U.S. LLC$188K
Eli Lilly$88K
Neurocrine Biosciences, Inc.$51K
plus $139K from 48 others

$36in research payments, 2019–2025

Across 2 payments — averaging $18.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$36

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	641	$567,438
Amgen(2 entities)	278	$237,851
Novo Nordisk	232	$198,995
Sanofi-aventis U.S. LLC	144	$187,514
Eli Lilly	27	$87,629
Neurocrine Biosciences, Inc.	40	$51,036
Boehringer Ingelheim	41	$33,590
Bayer	36	$31,165
Radius Health, Inc.	38	$30,685
AstraZeneca(2 entities)	56	$21,598
Merck	29	$12,179
IBSA Pharma Inc.	7	$2,066
Boehringer Ingelheim International GmbH	1	$2,000
Corcept Therapeutics	19	$1,198
Insulet Corporation	21	$505
Johnson & Johnson	9	$496
AbbVie	27	$414
Abbott	11	$380
Xeris Pharmaceuticals, Inc.	16	$298
Sequel Med Tech, LLC	4	$284
Ascensia Diabetes Care US Inc.	2	$189
Cequr Corporation	2	$167
Ascendis Pharma Endocrinology Inc	5	$161
Amryt Pharma Holdings Ltd	4	$151
Kyowa Kirin, Inc.	1	$122
Medtronic	14	$111
Dexcom, Inc.	1	$92
BETA Bionics, Inc.	1	$88
Recordati_rare_diseases_inc.	4	$80
Mannkind Corporation	4	$77
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$76
Sanofi	4	$68
Ipsen Biopharmaceuticals, Inc	2	$66
Novartis	3	$64
Ultragenyx Pharmaceutical Inc.	3	$55
Shire North American Group Inc	3	$43
Lexicon Pharmaceuticals, Inc.	2	$42
Antares Pharma, Inc.	2	$39
Biomarin Pharmaceutical Inc.	1	$38
Verity Pharmaceuticals Inc.	1	$29
Optos, Inc.	1	$23
EUSA Pharma (US) LLC	1	$19
Averitas Pharma Inc.	1	$19
Pfizer	1	$19
Azurity Pharmaceuticals, Inc.	1	$17
Acella Pharmaceuticals, LLC	1	$17
Amphastar Pharmaceuticals, Inc.	1	$17
Esteve Pharmaceuticals LLC	1	$16
GRT US Holding, Inc.	1	$15
Endo Pharmaceuticals Inc.	1	$15
Takeda Pharmaceuticals U.S.A., Inc.	1	$14
Ferring Pharmaceuticals Inc.	1	$13
Lifescan, Inc.	1	$12
Boston Scientific	1	$12

How this compares

$1,469,302 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee →

Medicare billing

Part B allowed, 2024

$100,242

Medicare patients

460

Services billed

2,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Memphis

Lisa UsdanMemphis$14.3M
Pedro VelasquezMemphis$2.4M
Aidar GosmanovMemphis$833K
Shimon HararyMemphis$735K
Samuel Dagogo-JackMemphis$476K
Ebenezer NyenweMemphis$438K
Richard ChildressMemphis$212K
Deirdre JamesMemphis$92K
Malini GuptaMemphis$91K
Benjamin BrannickMemphis$84K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →